Drug

RC48-ADC

As of the edition of 20 October 2026, RC48-ADC is a drug known only by a code name: in active development; acts on ERBB2, ESR1 and TUBA1A and 14 more.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Active, 2026
Kind
Code name only
Registered trials
21, 0 stopped early
Disease areas
Cancer; Digestive system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Targets

GeneProteinUniProt
ESR1Estrogen receptorP03372
TUBB4ATubulin beta-4A chainP04350
ERBB2Receptor tyrosine-protein kinase erbB-2P04626
TUBBTubulin beta chainP07437
TUBA3CTubulin alpha-3C chainP0DPH7
TUBA1BTubulin alpha-1B chainP68363
TUBA4ATubulin alpha-4A chainP68366
TUBB4BTubulin beta-4B chainP68371
TUBB3Tubulin beta-3 chainQ13509
TUBB2ATubulin beta-2A chainQ13885
TUBB8Tubulin beta-8 chainQ3ZCM7
TUBA3ETubulin alpha-3E chainQ6PEY2
TUBA1ATubulin alpha-1A chainQ71U36
TUBA1CTubulin alpha-1C chainQ9BQE3
TUBB6Tubulin beta-6 chainQ9BUF5
TUBB2BTubulin beta-2B chainQ9BVA1
TUBB1Tubulin beta-1 chainQ9H4B7

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 13200
Phase 215510
Phase 33010
All trials21

Who ran its trials

CompanyRoleYears
RemeGenLead sponsor of trials2015 to now